S
Sterling Biotech
STERLINBIO
Sterling Biotech
Healthcare Pharmaceuticals & Biotechnology
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Debtor days have improved from 42.9 to 32.1 days.
Weaknesses
3- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 2.07% over past five years.
- Contingent liabilities of Rs.1,015 Cr.
Growth Rate
Revenue Growth
19% higher than
3Y
Net Income Growth
65% higher than
3Y
Quarterly Results
| Particulars | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 87 | 113 | 95 | 88 | 96 | 91 | 95 | 89 | 88 | 80 | 84 | 82 | 95 |
| Expenses | 82 | 99 | 84 | 94 | 92 | 86 | 94 | 82 | 84 | 78 | 80 | 70 | 84 |
| Operating Profit | 6 | 14 | 11 | -6 | 4 | 5 | 0 | 7 | 4 | 2 | 4 | 12 | 11 |
| OPM % | 7% | 12% | 12% | -7% | 4.4% | 5% | 0.5% | 7% | 4.4% | 2.6% | 4.5% | 15% | 12% |
| Other Income | 0 | 3 | 1 | 0 | 1 | 1 | 1 | 2 | 1 | -765 | -3,008 | 2 | 1 |
| Interest | 89 | 83 | 80 | 95 | 97 | 98 | 103 | 112 | 111 | 114 | 237 | 148 | -102 |
| Depreciation | 70 | 66 | 66 | 66 | 66 | 66 | 67 | 61 | 61 | 61 | 61 | 61 | 61 |
| PBT | -153 | -132 | -134 | -167 | -158 | -158 | -167 | -165 | -168 | -938 | -3,303 | -195 | 53 |
| Tax % | -35% | -35% | -35% | -35% | -35% | -29% | -35% | 0% | 0% | -40% | -30% | -30% | 30% |
| Net Profit | -100 | -86 | -88 | -110 | -103 | -112 | -110 | -165 | -168 | -563 | -2,309 | -136 | 37 |
| EPS in Rs | -3.68 | -3.17 | -3.22 | -4.02 | -3.79 | -4.12 | -4.02 | -6.05 | -6.17 | -20.69 | -84.84 | -5 | 1.36 |
Profit & Loss
| Particulars | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Mar 2016 15m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,617 | 1,662 | 835 | 718 | 667 | 524 | 368 | 352 | 350 | 346 | 343 | 408 |
| Expenses | 920 | 1,121 | 687 | 623 | 587 | 460 | 356 | 338 | 306 | 536 | 305 | 461 |
| Operating Profit | 697 | 541 | 148 | 95 | 80 | 64 | 13 | 14 | 44 | -190 | 38 | -53 |
| OPM % | 43% | 33% | 18% | 13% | 12% | 12% | 3.4% | 4% | 13% | -55% | 11% | -13% |
| Other Income | -52 | 9 | 6 | 4 | 4 | 8 | 4 | -767 | -3,008 | 4 | 75 | 8 |
| Interest | 230 | 270 | 412 | 438 | 470 | 415 | 370 | 440 | 259 | 0 | 0 | 2 |
| Depreciation | 198 | 252 | 259 | 254 | 277 | 345 | 264 | 246 | 246 | 246 | 245 | 243 |
| PBT | 217 | 28 | -518 | -593 | -662 | -688 | -617 | -1,438 | -3,468 | -432 | -133 | -290 |
| Tax % | 33% | 31% | -32% | -32% | -31% | -34% | -33% | -30% | -4% | 0% | 536% | 2% |
| Net Profit | 145 | 19 | -350 | -401 | -458 | -450 | -412 | -1,005 | -3,330 | -432 | -844 | -295 |
| EPS in Rs | 5.42 | 0.71 | -13.06 | -14.96 | -16.82 | -16.55 | -15.15 | -36.94 | -122 | -15.89 | -31 | -10.85 |
| Div. Payout % | 9% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 |
| Reserves | 2,444 | 2,464 | 1,844 | 1,443 | 1,010 | 1,637 | 1,249 | 249 | -4,190 | -4,623 | -5,466 | -5,760 |
| Borrowings | 3,744 | 4,255 | 4,990 | 5,868 | 6,105 | 6,568 | 6,949 | 7,493 | 3,223 | 7,969 | 7,900 | 7,984 |
| Other Liabilities | 433 | 389 | 223 | 61 | 70 | 129 | 130 | 109 | 4,642 | 123 | 130 | 181 |
| Total Liabilities | 6,648 | 7,134 | 7,084 | 7,399 | 7,213 | 8,360 | 8,355 | 7,877 | 3,703 | 3,495 | 2,591 | 2,432 |
| Fixed Assets | 2,845 | 2,942 | 3,633 | 3,433 | 3,274 | 2,965 | 2,726 | 2,488 | 2,244 | 1,998 | 1,760 | 1,520 |
| CWIP | 1,263 | 1,646 | 1,552 | 2,110 | 2,270 | 2,450 | 2,442 | 2,503 | 0 | 0 | 0 | 0 |
| Investments | 364 | 365 | 377 | 377 | 169 | 1,552 | 1,582 | 1,586 | 2 | 2 | 3 | 3 |
| Other Assets | 2,176 | 2,182 | 1,522 | 1,479 | 1,500 | 1,393 | 1,604 | 1,299 | 1,457 | 1,495 | 829 | 909 |
| Total Assets | 6,648 | 7,134 | 7,084 | 7,399 | 7,213 | 8,360 | 8,355 | 7,877 | 3,703 | 3,495 | 2,591 | 2,432 |
Cash Flow
| Particulars | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 348 | 370 | 811 | 172 | 256 | 67 | 1 | -33 | 58 | 20 | 32 | 87 |
| Investing | -994 | -733 | -812 | -315 | 17 | -84 | -49 | -9 | -1 | 1 | -4 | 1 |
| Financing | 675 | 227 | -4 | 143 | -273 | 16 | 49 | 38 | -2 | 0 | 0 | 0 |
| Net Cash Flow | 29 | -136 | -4 | 0 | 0 | -1 | 0 | -4 | 55 | 21 | 28 | 88 |
| Free Cash Flow | -557 | -362 | 11 | -143 | 65 | -17 | -49 | -42 | 57 | 20 | 25 | 85 |
| CFO/OP | 54 | 76 | 550 | 183 | 320 | 114 | 5 | -233 | 132 | -11 | 84 | -164 |
Ratios
| Particulars | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 153 | 159 | 152 | 171 | 99 | 29 | 43 | 53 | 42 | 45 | 52 | 32 |
| Inventory Days | 313 | 419 | 547 | 566 | 498 | 739 | 939 | 88 | 91 | 101 | 134 | 117 |
| Days Payable | 23 | 18 | 17 | 14 | 19 | 23 | 51 | 30 | 35 | 25 | 36 | 28 |
| Cash Conversion Cycle | 442 | 559 | 682 | 722 | 577 | 745 | 931 | 112 | 98 | 121 | 149 | 121 |
| Working Capital Days | 427 | -145 | -1,060 | -1,812 | -965 | -1,042 | -2,008 | -5,340 | -6,017 | -6,299 | -6,272 | -5,392 |
| ROCE % | 9% | 6% | -2% | -2% | -3% | -4% | -3% | -3% | -6% | -36% | -5% | -12% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sterling Biotech insights
57 extracted metrics + investor summaries across FY10–FY22.
Documents
Frequently Asked Questions about Sterling Biotech
What does Sterling Biotech Ltd do?
Sterling Biotech is engaged in the manufacturing of Pharma Grade Gelatine & Di-Calcium Phosphate and other Pharma products The Company has presence in both domestic and international markets.
Which sector does Sterling Biotech Ltd belong to?
Sterling Biotech Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Sterling Biotech is engaged in the manufacturing of Pharma Grade Gelatine & Di-Calcium Phosphate and other Pharma products The Company has presence in both domestic and international markets.
Website sterlingbiotech.in
Face Value ₹ 1
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/STERLINBIO.md for Sterling Biotech Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.